Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ697MR)

This product GTTS-WQ697MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ697MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11638MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ14615MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ218MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ11044MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ9093MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ11213MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ10584MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ1133MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-927
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW